Substituted pyrazoles

Details Substituted pyrazoles Substituted pyrazoles

2008-07-01

2008-07-01

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S254070, C544S362000, C544S368000, C544S371000

Reexamination Certificate

active

07393850

ABSTRACT:
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.

REFERENCES:
patent: 3994890 (1976-11-01), Fujimura et al.
patent: 4500525 (1985-02-01), Winters et al.
patent: 5264576 (1993-11-01), Shutske et al.
patent: 5599815 (1997-02-01), Fukuda et al.
patent: 5776718 (1998-07-01), Palmer et al.
patent: 5830850 (1998-11-01), Gelb et al.
patent: 5976858 (1999-11-01), Palmer et al.
patent: 6020336 (2000-02-01), Lavielle et al.
patent: 6030946 (2000-02-01), Klaus et al.
patent: 6046204 (2000-04-01), Cooper et al.
patent: 6214813 (2001-04-01), Zhang et al.
patent: 6287840 (2001-09-01), Palmer et al.
patent: 2002/0040020 (2002-04-01), Breitenbucher et al.
patent: 2007/0004754 (2007-01-01), Beavers et al.
patent: 2007/0004755 (2007-01-01), Beavers et al.
patent: 2007/0010530 (2007-01-01), Beavers et al.
patent: 199714432 (1997-07-01), None
patent: 0254241 (1988-01-01), None
patent: 382637 (1993-07-01), None
patent: 502786 (1996-04-01), None
patent: 0747049 (1996-12-01), None
patent: 0902027 (1999-03-01), None
patent: 655248 (1999-09-01), None
patent: 1489280 (1977-10-01), None
patent: 50116470 (1975-09-01), None
patent: 52014765 (1977-02-01), None
patent: WO 94/18197 (1994-08-01), None
patent: WO 95/23222 (1995-08-01), None
patent: WO 96/30353 (1996-10-01), None
patent: WO 97/21439 (1997-06-01), None
patent: WO 97/40066 (1997-10-01), None
patent: WO 9856785 (1998-12-01), None
patent: WO 99/24460 (1999-05-01), None
patent: WO 99/48911 (1999-09-01), None
patent: WO 99/58153 (1999-11-01), None
patent: WO 00/49008 (2000-08-01), None
patent: WO 00/51998 (2000-09-01), None
patent: WO 00/55144 (2000-09-01), None
patent: WO 01/09110 (2001-02-01), None
patent: WO 01/19796 (2001-03-01), None
patent: WO 01/40204 (2001-06-01), None
Palmer, J.T. et al. Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. J. Med. Chem. 1995, 38(17), 3193-3196.
Bromme, D. et al., “Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors,” Biochem. J. 1996, 315, 85-89.
McGrath, M.E. et al., “Crystal structure of human cathepsin S,” Protein Sci. 1998, 7(6), 1294-1302.
Nerenberg, J.B. et al., “Design and Synthesis of N-Alkylated Saccharins as Selective α-1A Adrenergic Receptor Antagonists,” Boorg. Med. Chem. Lett. 1998, 8, 2467-2472.
Honey, K. et al., “Role of Lysosomal Cysteine Proteinases in Antigen Presentation on CD4 T Cells,” Inflammation Research 2001, Supp. 3, 50, S159, abstr. Oct. 2001.
Li, W. et al., “Tissue Specific Expression of Cathepsins and Antigen Presentation,” Inflammation Research 2001, Supp. 3, 50, S159, abstr. Oct. 2002.
Magill, C. et al., “Cysteine Proteases in Antigen Presentation and Models of Inflammation,” Inflammation Research 2001, Supp. 3, 50, S159, abstr. Oct. 2003.
Allen, E.M. et al, “Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo,” Inflammation Research 2001, Supp. 3, 50, S159, abstr. Oct. 2004.
Podolin, P.L. et al., “Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation in Vitro, and Reduces the Severity of Collagen-Induced Arthritis In Vivo,” Inflammation Research 2001, Supp. 3, 50, S159, abstr. Oct. 2005.
Spero, D. et al., “Design and Synthesis of Novel Cathepsin S Inhibitors,” Inflammation Research 2001, Supp. 3, 50, S206, abstr. 079.
Andronati, S.A. et al., “Synthesis of 1-{4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and 1H-indazoles and their affinity for benzodiazepine receptors,” Chemical Abstracts No. (CAN) 122:314528 (1994) 8:126-131.
Bromme, D. et al., “High level expression and crystallization of recombinant human cathepsin S,” Protein Sci. 1996, 5, 789-791.
Kirschke, H. et al., “Cathepsin S,” Handbook of Proteolytic Enzymes; Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624.
Nakagawa, T.Y. et al., “Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagaen-Induced Arthritis in Cathepsin S Null Mice,” Immunity 1999, 10, 207-217.
Riese, R.J. et al., “Cathepsin S Activity Regulates Antigen Presentation and Immunity,” J. Clin. Invest. 1998, 101(11), 2351-2363.
Shi, G.P. et al., “Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development,” Immunity 1999, 10, 197-206.
Singh, P. et al., “Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine,” Quant. Struct.-Act. Relat. 1990, 9, 29-32.
Winters, G. et al., “Synthesis, in Vitro [3H]Prazosin Displacement, and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive Agents,” J. Med. Chem. 1985, 28(7), 934-940.
Andronati, “Synthesis of 3-aryl-1-[4-phenyl-1-piperazinyl)butyl]iondazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors,” Pharmazie 1999, 54(2), 99-101.
Fujimura, Y. et al. “Indazole derivatives”, Database CA Online, Chemical Abstracts Service, STN database accession No. 87:53281, XP002193796 abstract (Feb. 3, 1977) relating to JP 52014765 (Chugai Pharmaceutical Co., Ltd.).
Fujimura, Y. et al. “Indazole derivatives.” Database CA Online, Chemical Abstracts Service, STN database accession No. 84:59450, XP002193797 abstract (Sep. 11, 1975) relating to JP 50116470 (Chugai Pharmaceutical Co., Ltd.).
Nakatsuka, M. et al. “Preparation of pyrazole derivatives as immunosuppressants.” Database CA Online, Chemical Abstracts Service, STN database accession No. 130:52417, XP002193692 abstract (Dec. 17, 1998) relating to WO9856785 (Sumitomo Pharmaceuticals Co., Ltd.).
Leroy et al. Cathepsin S Inhibitors. Exp. Opin. Ther. Patents 2004, 14(3), 301-311.
Eberlein-Konig, et al. Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late-phase cutaneous reactions associated with polle allergen-specific immunotherapy. Clin. Exp. Allergy 1999, 29(12), 1641-1647.
Gaga, et al. Eosinophil activation and T lymphocyte infiltration in allergin-induced late phase skin reactions and classical delayed-type hypersensitivity. J. Immunol. 1991, 147, 816-822.
Chapman, H.A. et al. Emerging Roles for Cysteine Proteases in Human Biology. Ann. Rev. Physiol. 1997, 59, 63-88.
Chapman, H.A. Endosomal Proteolysis and MHC Class II Function. Curr. Opin. Immunol. 1998, 10, 93-102.
Maurer, D. et al. Fce Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S-Dependent Pathway of MHC Class II Presentation. J. Immunol. 1998, 161, 2731-2739.
Nakagawa, T.Y. et al. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol. Rev. 1999, 172, 121-129.
Riese, R.J. et al. Cathepsins and Compartmentalization in Antigen Presentation. Curr. Opin. Immunol. 2000, 12, 107-113.
Villadangos, J.A. et al. Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatability Complex Polymorphism. J. Ex. Med. 1997, 186(4), 549-560.
Villadangos, J.A. et al. Proteases Involved in MHC Class II Antigen Presentation. Immunol. Rev. 1999, 172, 109-120.
Villadangos, J.A. et al. Proteolysis in MHC Class II Antige Presentation: Who's in Charge? Immunity 2000, 12, 233-239.
Paluchowska et al. Structure-activity relationship studies of CNS agents. 40. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022. Pol. J. Pharmacol. 1999, 51(5), 415-421.
Paluchowska et al. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system. Pol. J. Pharmacol. 2000, 52(3), 209-216.
Reise, R.J. et al. Essential Role for cathepsin

Affiliated with

Also associated with

Rating

Substituted pyrazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2781736